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Abstract: Poly(ethylene glycol) (PEG) is widely used as a gold standard in bioconjugation and
nanomedicine to prolong blood circulation time and improve drug efficacy. The conjugation of PEG
to proteins, peptides, oligonucleotides (DNA, small interfering RNA (siRNA), microRNA (miRNA))
and nanoparticles is a well-established technique known as PEGylation, with PEGylated products
have been using in clinics for the last few decades. However, it is increasingly recognized that treating
patients with PEGylated drugs can lead to the formation of antibodies that specifically recognize and
bind to PEG (i.e., anti-PEG antibodies). Anti-PEG antibodies are also found in patients who have
never been treated with PEGylated drugs but have consumed products containing PEG. Consequently,
treating patients who have acquired anti-PEG antibodies with PEGylated drugs results in accelerated
blood clearance, low drug efficacy, hypersensitivity, and, in some cases, life-threatening side effects.
In this succinct review, we collate recent literature to draw the attention of polymer chemists to
the issue of PEG immunogenicity in drug delivery and bioconjugation, thereby highlighting the
importance of developing alternative polymers to replace PEG. Several promising yet imperfect
alternatives to PEG are also discussed. To achieve asatisfactory alternative, further joint efforts
of polymer chemists and scientists in related fields are urgently needed to design, synthesize and
evaluate new alternatives to PEG.
Keywords: PEGylation; anti-PEG antibody; PEG immunogenicity; drug delivery; bioconjugation;
nanomedicine; cancer; vaccine
1. PEGylation in Bioconjugation and Drug Delivery
Poly(ethylene glycol) (PEG) is a synthetic polymer that is well-suited for biomedical applications
due to its high solubility in aqueous media, biocompatibility, and good tolerance. PEG-conjugated drugs
have been approved by the U.S. Food and Drug Administration (FDA) for safe use in humans [1–4].
Consequently, PEG has been widely utilized in biomedical applications such as bioconjugation, drug
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delivery, biosensing, imaging, and tissue engineering. In bioconjugation and drug delivery, PEG is
either directly conjugated with drugs or attached to the surface of drug-encapsulating nanomaterials
(a technique known as PEGylation) to augment in vivo stability and solubility and to reduce clearance
rate from circulation, thus optimizing drug efficacy [5–7]. Since the 1970s, numerous PEGylation
strategies have been utilized for different products in various biomedical applications. Review articles
on the topic of PEGylation and its applications can be found in the literature and, hence, PEGylation is
not the focus of this review [2,8–15]. For example, Veronese et al. highlighted the most popular PEG
derivatives by using various conjugation strategies, with the critical parameters of PEG structure and
molecular weight (MW) needed to achieve good efficacy of PEG-conjugated drugs reported [3,14].
In addition to the direct bioconjugation of PEG to drugs, PEGylation has been widely utilized
for the biomedical applications of nanomaterials. Nanoparticles (NPs), as materials with a wide
range of physicochemical properties that are generally sized at a 1–100 nm scale, are considered to be
promising candidates for a drug carrier system because they can be readily engineered to have a high
stability, a high ratio of surface area/volume, easy modification with targeting agents, and the capacity
to carry a high payload of the treatment agents [16–18]. Properties of NPs such as size, shape, and
surface chemistry can be tuned to improve stability, direct specific interactions with cells, and alter
their biodistribution profile [19–22]. Few candidates, however, have progressed from the benchtop
to the market [23,24], with factors such as a limited in vivo stability and undesirable off-target effects
likely contributing to a lack of translational success [10]. PEGylation has been shown to improve the
in vivo stability of micelles, liposomes, dendrimers, gold nanoshells, quantum dots and polymeric
NPs, thus providing more effective therapeutic action [7,25]. PEG-modified NPs become hydrophilic
and attain near-zero zeta potential, thus preventing or minimizing the attachment of opsonins (serum
proteins) that confer an increased likelihood of phagocytosis. Consequently, PEGylated NPs can avoid
the mononuclear phagocyte system [3,7]. PEG chains with high hydration levels could further augment
the hydrodynamic size of PEG-modified NPs to protect them from renal clearance, as well as limiting
the access of proteolytic enzymes and antibodies [26]. As a result, PEGylation can provide NPs with
a significantly improved circulation lifetime compared to unmodified NPs, further extending these
properties to any encapsulated drugs in PEG-based delivery systems [27]. Additionally, the flexible
hydrophilic PEG chains could allow PEG-modified NPs to quickly diffuse through mucin fibers
for the effective local release of drugs [9,28]. Suk et al. summarized the effects of PEG content,
its molecular weight, NP core properties, and timepoints of administration in order to understand
the optimal conditions to deliver adequate concentrations of therapeutics to evade immune detection
and prolong circulation time [2]. Methods of PEG density quantification, including both indirect and
direct techniques, were also outlined. By considering NP PEGylation within the context of current
biomedical approaches, it was concluded, in accordance with other research, that functionalization
with PEG could improve the systemic delivery of NPs [9,29].
After several decades of development and clinical use, PEGylation is still limited by several factors,
and it faces emerging challenges that significantly impact its biomedical applications going forward [30].
While the PEGylation of materials can increase their solubility, the molecular weight (MW) of PEG
requires optimization to achieve prolonged circulation while retaining drug activity [3]. Accordingly,
PEG with an MW less than ~60 kDa is excreted by the kidneys, while higher MW PEG chains are
excreted in the feces [3]. The non-biodegradability of PEG limits the capacity of the kidneys to clear it,
thus promoting PEG accumulation in the liver and in lysosomes of normal tissues. The accumulation
of high MW PEG in the liver, in particular, can cause macromolecular syndrome. In addition, the
PEGylation-induced enlargement of NPs may increase the reticuloendothelial system (RES) uptake,
resulting in an unfavorably fast release of drug cargoes. The hydrophilicity of PEG chains that support
NP penetration through mucus layers via a diffusion mechanism also confers a reduced intracellular
uptake. These limitations, as well as related solutions, have been highlighted in other reviews [31–40].
This article focuses on a more challenging issue in PEGylation—PEG immunogenicity.
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Figure 1. Different materials at the nanoscale: the various types of synthetic nanoparticles (NPs) are 
generally sized at 1–100 nm, which is comparable with native nanostructures including proteins, 
viruses and DNA. Poly(ethylene glycol) (PEG) is conjugated to NP surface to form PEG-NPs, 
providing a number of advantageous properties within a drug delivery system. A limitation of 
PEGylated NPs at the biological interface is the development of anti-PEG antibodies: anti-PEG 
immunoglobulin M (IgM) is induced after the first dose of PEG-NPs, and it quickly recognizes PEG-
Figure 1. Different materials at the nanoscale: the various types of synthetic nanoparticles (NPs)
are generally sized at 1–100 n , which is co parable with native nanostructures including proteins,
viruses and DNA. Poly(ethylene glycol) (PEG) is conjugated to NP surface to form PEG-NPs, providing
a number of advantageous properties within a drug delivery system. A limitation of PEGylated NPs
at the biological interfac is the development of anti-PEG antibodies: anti-PEG immunoglobulin M
(IgM) is i duced after the first dose of PEG-NPs, and it quickly recognizes PEG-NPs in the second dose.
Kupffer cells in the liver are then directed to activate the complement system and remove PEG-NPs.
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The administration of PEGylated drugs can lead to the production of anti-PEG antibodies
(anti-PEG immunoglobulin M (IgM)) and immune response (Figure 1) [30]. Due to these phenomena,
the PEG-conjugation of drugs/NPs often only provides a biological advantage during the first dose
of a treatment course. By the second dose, the PEGylated agents have been recognized by the
mononuclear phagocyte system in the spleen and liver and are rapidly cleared from circulation.
This unexpected immunogenic reaction, which causes the rapid clearance and decreased efficacy of
therapeutic agents, is defined as the accelerated blood clearance (ABC) phenomenon [41,42]. Anti-PEG
IgM, in particular, has been noted as an important marker of and a major contributor to the ABC
of PEGylated nanomaterials. Several clinical studies have reported that anti-PEG IgM could be
even detected in healthy patients without prior exposure to PEGylated drugs [43,44]. Consequently,
the impact of the anti-PEG IgM-mediated clearance of PEGylated NPs has been identified as an
emerging challenge to the design of PEG-associated treatment strategies. Luo et al. confirmed that
PEGylated graphene oxide (nGO-PEG) induced strong immunological responses due to the physical
interfacing of nGO-PEG to the macrophage membrane, resulting in improved cell mobility and
migration [45]. Consequently, the greatly accelerated production of activation-associated cytokines,
including interleukin-6, monocyte chemotactic protein-1, tumor necrosis factor-α, interferon-γ and
interleukin-12, were generated by the activated macrophages, with cytokine levels reportedly in direct
proportion to nGO-PEG dosages. Lai et al. additionally reported that Kupffer cells further contribute to
PEG-related ABC. Kupffer cells are a type of antigen-presenting cell (APC) that act as a bridge between
the innate and adaptive immune systems, and they have been shown to clear PEGylated liposomes
from the body after their detection with anti-PEG antibodies [46].
2. PEG Immunogenicity in Animals and Humans
2.1. PEG Immunogenicity in Animals
In 1983, Richter and Akerblom reported for the first time the detection of anti-PEG IgM in vivo in
a rabbit model [33]. The authors utilized PEGylated ovalbumin (OVA), bovine superoxide dismutase
(SOD) and pollen extract, demonstrating that anti-PEG IgM production occurred after the injection
of the PEGylated OVA while the free OVA and SOD did not induce immune activation [33]. In this
context, PEG has been compared to hapten: [33] a nonimmunogenic compound able to trigger
antibody production when interfaced with an immunogenic protein [47]. Caliceti et al. studied the
immunological properties of uricase that was conjugated with a branched monomethoxy PEG (mPEG;
MW of 10 kDa) and linear mPEG (MW of 5 kDa) in mice models [48]. They found that low levels of
anti-PEG IgM were generated after the second immunization of PEGylated uricase [48]. PEGylated
liposomes have demonstrated rapid clearance in rat, guinea pig, minipig and beagle dog models after
each consecutive dose following their second administration [33,49,50]. Anti-PEG IgM levels varied,
however, depending on the immunological sensitivity of different models, thus eliciting differential
impacts of ABC. Recently, Moreno et al. utilized PEGylated RNA aptamers to test anti-PEG antibodies
in a monkey model, and they found that the repeated administration of PEGylated drugs could
trigger anti-PEG antibody production in animal models [51]. The production of anti-PEG antibodies is
illustrated in Figure 2a.
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Figure 2. Repeated administration of PEGylated drugs (PEG-drugs) or PEGylated nanoparticles
(PEG-NPs) triggers anti-PEG IgM production in animal models (a) and in humans (b), and it causes the
accelerated blood clearance (ABC) phenomenon. In the case of patients with pre-existing anti-PEG IgM,
the ABC phenomenon occurs upon the first administration of PEG-drugs or PEG-NPs. (c) Illustration
of the increase of pre-existing anti-PEG IgM over the last couple of decades.
2.2. PEG Immunogenicity in Humans
Over the last couple of decades, free PEGs have been utilized for numerous applications such
as osmotic laxatives, topical medications, cosmetics, and in various other household and consumer
products [26,38,52]. Consequently, many patients have previously been exposed to PEG, resulting
in the detection of anti-PEG antibodies in human blood prior to the administration of PEGylated
drugs/NPs (Figure 2b,c) [44,53,54]. The percentage of human with pre-existing anti-PEG IgM have
increased significantly from 1984 to 2016. In 1984, Richter and Åkerblom reported that 0.2% of the
healthy blood donor population and 3.3% of allergic patients contained anti-PEG antibodies [52].
Almost 20 years later, Armstrong et al. reported that more than 25% of healthy blood donors exhibited
anti-PEG antibodies [38,52], and, in 2016, Yang et al. reported that the prevalence of anti-PEG antibodies
in untreated patients was up to 70% [51]. The increasing number of patients with innate anti-PEG
antibodies may be related to the consumption of more products that contain PEG. In the case of
pegnivacogin, an RNA aptamer that is conjugated with 40 kDa branched mPEG, the presence of
pre-existing anti-PEG antibodies induced an unexpected, life-threatening condition: after exposure to
pegnivacogin at the first trial, acute coronary syndrome developed in anti-PEG positive patients [26].
Consequently, PEG-containing drugs such as pegloticase, or even free PEG in drug formulations, could
trigger severe allergic reactions in patients with high levels of anti-PEG antibodies [26,52]. These studies
demonstrate that anti-PEG antibodies are capable of limiting drug activity, but, more importantly,
patients who harbor anti-PEG antibodies should consider how PEG hypersensitivity may impact
their health before treatment with PEG-based agents. In particular, depending on the magnitude
of pre-existing anti-PEG antibodies, reactions within every patient may be different, necessitating
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assessment on a case-by-case basis. Thus, clinicians should advise that all patients prescribed PEGylated
drugs should be examined for the presence of anti-PEG antibodies in order to preserve patient health
and safety and maximize the efficacy of the treatment course [44,53].
As more PEGylated therapeutics enter the clinic, the investigation of anti-PEG antibody impacts
with regards to each product is increasingly important in order to avoid adverse effects in treated
patients [26]. For Krystexxa, an mPEG-10kDa-uricase compound, 38% of patients who were
administered with either a single subcutaneous or intravenous injection tested positive for anti-PEG
antibodies. With a repeated treatment of Krystexxa, even with a one-year interval between two doses,
the rapid generation of anti-PEG antibodies occurred, resulting in a loss of therapeutic efficacy of the
drug [26]. In another case, PEG-asparaginase was generated and commercialized as Oncaspar for the
treatment of acute lymphoblastic leukemia (ALL). Similarly to observations with other PEGylated
drugs, anti-PEG antibodies were also detected in all patients treated by Oncaspar [26]. To limit the
development of patient hypersensitivity to Oncaspar, a similar drug, PEG-crisantaspase, has been
developed—however, as a newly synthesized drug, the characterization of PEG-crisantaspase is
lacking [26].
3. Factors Affecting PEG Immunogenicity
3.1. Effect of Time Intervals between First and Second Doses of PEGylated Drugs
As has been previously described, the production of anti-PEG IgM following an initial dose of
PEGylated drugs/NPs is causative of the ABC phenomenon [55]. Li et al. reported that a PEGylated
liposomal topotecan (pLT) could induce ABC in beagle dogs after repeated injection [55]. The time
interval between intravenous injections of pLT was altered and plasma IgM was assessed in order to
determine the magnitude of PEG-associated ABC. When the time interval between the first dose and
second dose was seven days, a rapid clearance of ~95% of the second pLT dose was observed—however,
when the interval was increased to 21 days, only 52% of the second pLT dose underwent ABC. By the
28 day interval, the clearance kinetics of both doses demonstrated no significant variation, indicating
that ABC did not take place. Concurrently, plasma IgM after the first pLT dose was assessed to
interrogate the correlation between anti-PEG IgM and ABC. Anti-PEG IgM was detected after initial
exposure to both pLT and the ‘empty’ PEGylated liposomes, with the level of anti-PEG IgM increasing
gradually to peak at day seven, followed by a decrease to the basal level by day 28. Taken together,
the lower levels of plasma IgM resulted in the mitigation of PEG-associated ABC by 28 days post
initial pLT administration—indicating that the generation of anti-PEG IgM after the first pLT dose
was directly proportional to the magnitude of PEG-associated ABC and supporting the conclusions of
additional studies [56].
Fengling et al. fabricated PEGylated liposomal gambogenic acid (PEG-GEA-L; 2 kDa) in order to
evaluate the contribution of anti-PEG IgM to ABC via repeated intravenous injection of PEGylated
liposomes in rat models [57]. After the initial dose of PEG-GEA-L, two injections at a fixed dosage
concentration (1.5 mg/kg) were then administered every three, five, and seven days. Anti-PEG
IgM antibodies were detected after the second dose, with plasma IgM levels peaking at the three
day interval and gradually decreasing when administration was delayed to five and seven days
(Figure 3a). Concomitantly, plasma GEA was also assessed, with a significant increase observed when
the time interval between two injections was extended. Pharmacokinetic parameters for repeated
doses demonstrated that ABC occurred after the second injection of PEG-GEA-L, clearly indicating
that repeated PEG-GEA-L treatment with a three day interval between two doses could trigger the
highest anti-PEG IgM production and the fastest blood clearance of PEG-GEA-L.
Taken collectively, these studies indicate that a dosage interval of under two days or over
21 days can effectively prevent the fast clearance of PEGylated liposomes mediated by anti-PEG
IgM production [42,50]. This can potentially be explained by the circulation half-life of the anti-PEG
antibodies, as anti-PEG IgM could be generated three-to-four days after initial injection, and have been
Polymers 2020, 12, 298 7 of 21
shown to disappear from plasma after three weeks in new-born pig [50], mice and rat models [58]
(Figure 3b).
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injec ed with PEGyla liposomal gambogenic cid (PEG-GEA-L) at 1.500 mg/kg (a) [57]. Mice were
treated w th PEGylated liposomes of 1 µmol/kg, and the productio of anti-PEG IgM in mouse sera was
deter ined as function of time (b) [58]. The effect of PEG-GEA-L doses on anti-PEG IgM production
was recorded n the fifth day after the first injection. Rats w re treat d with low (1.125 mg/kg), medium
(1.500 mg/kg), and high (1.875 mg/kg) dosages. ELISA was utilized to determine anti-PEG IgM (c).
Anti-PEG IgM in organ tissues of rats that were intravenously injected with various PEG-GEA-L doses
(d). Used with permission from [57]. (* p < 0.05, ** p < 0.01).
3.2. Effect of Different Doses at the Initial Injection
In a study undertaken by Fengling et al., the authors reported that the co-administration of
GEA and bare PEG-L liposomes could induce lower ABC than that of PEG-GEA-L after repeated
exposure to rat models [57]. When GEA encapsulated in PEG-L liposomes was administrated at
different concentrations in the second dose (1.125, 1.500, and 1.875 mg/kg), ABC was triggered, but the
rate of PEG clearance was not found to be dose-dependent. Conversely, when varying the first
dose of PEG-GEA-L with the second dose fixed at 1.5 mg/kg, ABC, after the second dose, increased
with higher drug concentration in the first dose (Figure 3c,d). Furthermore, the GEA released from
PEG-GEA-L accumulated in the liver and spleen at higher levels when the first dose was administered
at a higher concentration, indicating a proportional correlation between initial dose concentration
and ABC. In both these cases, it was implied that an immune response was only induced after the
first dose, resulting in the rapid clearance of the second dose [57]. However, when considering the
aforementioned native variation in circulating anti-PEG antibodies, dosage schedules of PEGylated
nanomedicines should ideally be tailored to individual patients to ensure analogous outcomes.
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3.3. Effect of PEG-Surface Density and Content, Molecular Weight and Functional Groups of PEG
PEG can be classified as an epitope in basic immunology, so the PEG content/density on the
surface of nanomaterials is one of the most important factors that impacts anti-PEG IgM responses.
Several studies [59] have found a correlation between PEG content and anti-PEG IgM induction, and a
number of reviews have interrogated the topic [37,42,50]. Bertrand et al. synthesized PEG-PLGA NPs
to investigate the effect of PEG densities on NP pharmacokinetics [59]. They found that a critical value
of PEG density was 20 PEG chains (MW of 5 kDa) per 100 nm2. PEGylated nanoparticles with either
lower or higher PEG density to the critical value could induce a fast or slow clearance, respectively.
When considering continuously increasing PEG density, it was shown that high PEG densities did not
significantly impact NP clearance from circulation [59], though discussion of the relationship between
clearance and anti-PEG IgM production, as a known causative factor of ABC, was omitted [37]. Ishida
et al. found that 5 mol% mPEG2000-liposomes maximally induced ABC, while both concentration
reduction and increase beyond this value caused a decline in ABC [42]. Recently, an additional study
by Li et al. demonstrated that a high PEG percentage (9%) on lipid nanoparticles could lead to a more
rapid clearance comparative to a low PEG percentage (3%). Zhao et al. reported that trends relating to
ABC versus PEG percentage were conserved across NPs with similar material constitutions.
By varying PEG surface densities, the circulation time of PEGylated lipid nanoparticles after the
initial dose can be tuned, consequently eliciting control over PEG-associated ABC [60]. In contrast,
Ishihara et al. reported no apparent relationship between PEG content and the ABC phenomenon [61].
In the case of PEGylated protein, Richter and Akerblom concluded that a high density of PEG
modification could lead to weaker antibody responses, potentially due to the enhanced masking
of immunogenic epitopes [26]. The molecular weight of incorporated PEG has also been shown to
affect its circulation time, though its impact is likely less significant at a lower MW—for example,
ABC was shown to be comparable between 2 and 5 kDa PEG [42]. Quach et al. investigated how
varying PEG MWs (1, 2, 5, and 10 kDa) that were conjugated on gold NPs impacted their phagocytosis,
demonstrating that a higher PEG MW minimized the macrophage recognition of the conjugated
NPs. This phenomenon can be explained by an increased NP hydrophilicity that was correlated with
increasing PEG MW, consequently decreasing the absorption of complement proteins and thus limiting
the activation of the complement system [62]. Further increasing PEG MW, however, can induce the
opposite effect. Han et al. reported that PEGylated interferon-alpha 2a had an improved circulation time
when functionalized with 20 kDa PEG instead of 10 kDa PEG [63]. Consequently, surface PEG density
and molecular weight are two critical factors to be optimized to ensure a minimal PEG-associated
immune response [64].
Functional groups appended to PEG chains are an additional factor that impacts their immunogenicity
(Figure 4). Shimizu et al. fabricated various PEGylated liposomes (PL) with different functional groups,
including methoxy (OCH3), amino (NH2), carboxyl (COOH), and hydroxyl (OH) moieties, and they
investigated anti-PEG IgM production and the clearance of PLs as a function of PEG end groups [65].
Four types of PLs were similarly sized (100.3 ± 13.8–111.9 ± 8.0 nm) but differentially charged as a
result of their functional groups (zeta potentials: −5.3 mV for PL-NH2, −19.2 mV for PL–OH, −26.4 mV
for PL–OCH3, and −32.3 mV for PL–COOH). PLs were intravenously injected into mice at 0.25 µmol
phospholipids/kg, and anti-PEG IgM levels were determined by ELISA five days post-injection.
All PLs induced anti-PEG IgM production, with PL–OH found both the least immunogenic and least
antigenic among the four types. PL–OH did, however, undergo more rapid clearance comparative
to PL–OCH3, with this trend conserved upon the administration of a second dose. This is likely
due to the propensity for hydroxyl groups to activate the complement system, which is a major
mechanism for the clearance of foreign materials. Research by Wang et al. was concordant with
these findings, with the authors further investigating the immunogenicity of PEG thiols (-SH) [66].
It was suggested that thiol groups could support B cell proliferation and differentiation, potentially
playing a stimulatory role in the PEG-associated immune response [66]. More recently, Joh et al.
proposed poly(oligo(ethylene glycol) methyl ether methacrylate) (POEGMA) as a next-generation PEG
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derivative for drug delivery, as it was shown to reduce anti-PEG antigenicity without compromising its
stealth properties. This study additionally demonstrated that OH moieties provide a superior immune
avoidance, with the hydroxyl-terminated ethylene glycol of POEGMA displaying a lower antigenicity
than the methoxy-terminated molecule [67].
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Figure 4. Production of anti-PEG Ig in the seru of mice injected PEGylated liposomes (PL)
with various functional groups were determined by ELISA on the fifth day after administration.
The lowest immunogenicity was exhibited by PL–OH (a). C3 binding in the serum of mice injected
P–OCH3 and PL–OH on the fifth d y, with non-t eated mice as the control sample. Sera were
diluted with a gelatin veronal buffer with Mg++ and Ca++ (GVB++) buffer (b) and an Mg2+/ethylene
glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) buffer (c). Mice treated with PL–OH
demonstrated the highest compliment activation, driving the ABC phenomenon (d). Used with
permission from the European Journal of Pharmaceutics and Biopharmaceutics [65]. Production of
anti-PEG IgM rat sera against PEGylated emulsions (DE) with various functional groups seven days
post-administration (e). Used with permission from the European Journal of Pharmaceutics and
Biopharmaceutics [66]. (* p < 0.05, ** p < 0.01, *** p < 0.001).
3.4. Effect of Nanoparticle Properties
In the context of PEG-functionalized NPs, the physicochemical properties of NPs (e.g., size and
charge) can further augment the production of anti-PEG antibodies upon systemic administration.
Koide et al. demonstrated that polymeric micelles with dimensions of less than 31.5 nm could effectively
avoid immune cells, while those larger than 50.2 nm triggered anti-PEG ABC [42]. Interestingly,
research by Abu Lila and colleagues, who utilized PEGylated liposomes, illustrated that the size (100,
400 and 800 nm) and charge (+13.15, −46.15 and −1.51 mV) of the first liposome dose did not affect
ABC induction, potentiating a highly variable impact of NP properties on anti-PEG immune response
that merits further investigation [42].
3.5. Effect of Administration Route
The administration modes of PEGylated particles have also been considered as major factors
that impact PEG-associated ABC [42]. Li et al. highlighted bolus intravenous administration as less
causative of ABC comparative to the slow infusion of the same PEGylated liposome dose, likely due
to the slower slow rate of exposure allowing for the development of a robust immune response [42].
Subcutaneous injection was additionally seen to enhance the ABC of PEGylated nanocarriers upon
repeated administration [42].
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3.6. Effect of an Encapsulated Drug
Drug cargoes of PEGylated NPs have reportedly contributed to ABC. Plasmid DNA encapsulated
in PEG-coated lipid NPs has been shown to induce a significantly higher anti-PEG IgM response
comparative to ‘empty’ NPs. Similar observations have been associated with other nucleic acid cargoes,
such as short interfering RNA, oligonucleotides, and RNA ribozymes. This is likely due to the strong
stimulatory effect of DNA motifs on toll-like receptor 9 (TLR9) that engenders an overarching increase in
NP immunogenicity [42]. Contrastingly, PEGylated liposomes carrying cytotoxic drugs were not found
to induce ABC after repeated injections [42], with non-cytotoxic agents incorporated inside PEG-coated
NPs additionally showing little to no impact on anti-PEG IgM-producing B cell populations.
Qi et al. utilized a low MW PEG (2 or 5 kDa) that lacked a methoxyl moiety as a linker
to conjugate arabinogalactan (AG) to staphylokinase (SAK) [68] in order to enhance SAK efficacy
through a reduction of immunogenicity, improved half-life and stabilized bioactivity. AG is a 38 kDa
polysaccharide macromolecule that, when interfaced with SAK, significantly increases the molecular
weight of the complex, allowing for avoidance of glomerular filtration. A low MW PEG that lacks
methoxyl has been shown to additionally trigger a weak anti-PEG immune response and to decrease
the steric shielding effect of AG. Subsequently, AG-PEG-SAK conjugation did not induce any AG-
or PEG-specific immune response, and it significantly enhanced the therapeutic efficacy of SAK [68].
Thus, cell membrane-camouflaged NPs could serve as an alternative to PEGylation without the
undesirable generation of anti-PEG antibodies, with the modified NPs gaining additional functionality
by harnessing the inherent properties of the incorporated membrane protein such as improved
biocompatibility and cell contact.
In summary, key factors that affect anti-PEG immune response and ABC have been reported and
explored, including: the dosage method and scheduling of PEGylated agents, the characteristics of
encapsulated drugs and NPs, and the physicochemical properties of PEGylated nanocarriers (diameter,
surface charge, and functionalized PEG density, conformation and functional groups) (Figure 5).
Further investigation and the fine-tuning of each factor during the design of PEGylated materials
and treatment strategies are thus paramount to limit anti-PEG immune response and to ensure their
efficacious application. Furthermore, clinicians should establish patient baseline anti-PEG IgM levels
in order to adjust treatment methods for avoiding the fast clearance of the PEGylated agent and any
adverse impacts on patient health.
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4. Potential PEG Alternatives
4.1. Hydrophilic Polymers
Due to the anti-PEG immune response that limits the efficacy of PEGylated treatment strategies,
many researchers have attempted to develop alternative polymers that mimic the physicochemical
properties of PEG without compromising therapeutic pharmacokinetics. The advantages and limitations
of these strategies are outlined in Table 1. Instead of using long and linear PEG chains, shorter
hyperbranched polymers could be utilized to mitigate antigenicity without compromising stealth
behavior. Joh et al. modified PEG into a bottlebrush architecture to overcome PEG-associated
ABC [67], thus presenting POEGMA as an alternative to linear PEG. The synthesized POEGMA had
a 3D hyperbranched structure with many side chains of oligoethylene glycol (EG) moieties [69,70]
and possessed effective stealth properties. Drug-conjugated hyperbranched POEGMA with nine
units of EG (EG9) significantly decreased PEG antigenicity in patient plasma when compared
to Krystexxa, an FDA-approved PEGylated protein drug. By varying the number of EG units,
it was additionally demonstrated that increasing EG content provided a higher wettability,
leading to improved protein anti-fouling. However, to avoid binding of anti-PEG antibodies,
POEGMA brushes with fewer side chains were found to be more favorable—POEGMA with
two-to-three EG units achieved both non-antigenicity and non-specific protein adsorption [67].
Other synthetic polymers such as poly(glycerols) (PGs), poly(oxazolines) (POX), poly(hydroxypropyl
methacrylate) (PHPMA), poly(2-hydroxyethyl methacrylate) (PHEMA) [71], poly(N-(2-hydroxypropyl)
methacrylamide) (HPMA), poly(vinylpyrrolidone) (PVP), poly(N,N-dimethyl acrylamide) (PDMA),
and poly(N-acryloylmorpholine) (PAcM) (Figure 6) have also been used to replace PEG, and their
synthesis and innate properties are reviewed elsewhere [26,28,72,73].
PGs are hyperbranched, non-immunogenic and highly hydrophilic, with a low viscosity in
aqueous solution and good biocompatibility. As such, PG-based drugs have demonstrated robust
blood circulation times and low immunogenicity, but they have been shown to accumulate highly
within the liver and kidneys, providing a disadvantage to their development as a drug delivery
system [72]. PGs have been shown to be less susceptible to oxidative or thermal stress than PEG [28]
and, importantly, unlike PEGylated agents, PG-based drugs do not undergo ABC after repeated
administration [73]. As illustrated in a study that utilized PG-modified liposomes, this phenomenon
could be explained by the steric hindrance of PG molecules at their surface: This limits the interfacing
of PG-liposomes and immunoglobulins on splenic B cells, preventing their stimulation and subsequent
generation of anti-polymer antibodies [50]. POX are thermosensitive polymers and retain good
solubility in both hydrophilic and hydrophobic solvents [72], and they have been reported to be both
highly resistant to oxidative degradation and not undergo bioaccumulation [28]. POX has conferred
stealth capability and good permeation through mucosal tissues when grafted to silica NPs, gold NPs,
ZnO nanocrystals, and magnetic NPs [73,74]. The current disadvantages of POX as a PEG alternative
include the high cost of synthesis, issues with impurities, difficulty to synthesize and to obtain FDA
approval, consequently rendering POX an imperfect PEG alternative [28,73].
Poly(acrylamide) and poly(methacrylamide) are well known as nonionic polymers with various
conformations, and are popular materials in biomedical applications. Though the polymeric
conjugations are non-immunogenic and, accordingly, have a low blood clearance rate, the highly
toxic monomers limit their development as PEG alternatives [72,73]. The poly(N-(2-Hydroxypropyl)
methacrylamide) (PHPMA), however, has demonstrated an excellent preclinical efficacy as a carrier
for chemotherapeutic drugs and has recently entered clinical trials [72], arguably presenting as one
of the best candidates for PEG alternatives. However, studies into the immune response of PHPMA
remain elusive.
PVP has a number of properties that present it as an attractive alternative to PEG, including
high hydration, good biocompatibility, and low immunogenicity. Historically, PVP-based materials
have been utilized for numerous applications within various fields. However, due to their unclear
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immunological behavior, non-biodegradability, and propensity for bioaccumulation, in addition to
the carcinogenic nature of free monomers, the development of this polymer for biomedical use has
been limited [26,72,73]. Among the aforementioned synthetic polymers, PG, PVP, and PHPMA have
been considered as the most promising alternatives to PEG [20]. However, the repeated administration
of these polymers and/or NP-polymer conjugates may still trigger the production of anti-polymer
antibodies, and further studies are needed to fully elucidate their immunogenic profiles [75,76].
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Glycosaminoglycans (GAGs) are long, unbranched and negatively charged polysaccharide chains
that contain two alternating monosaccharides, and are endogenously located at the cell surface and/or
extracellular matrix. Among GAGs, heparin and hyaluronic acid (HA) have found frequent applications
in preventing the recognition of NP conjugates by macrophages, with heparin- or HA-coated NPs
consistently demonstrating an increased circulation time comparative to non-functionalized NPs.
The innate properties of each GAG provide further synergistic benefits, i.e., the capacity of heparin
to act as an anticoagulant and a targeting ligand of HA. Polysialic acid (PSA), a homopolymer of
α2,8-linked sialic acid, is a naturally biodegradable and biocompatible monosaccharide that has also
been demonstrated as an effective coating agent. PSA-coated micelles that are utilized for anticancer
applications have a prolonged half-life and an antitumor effect similar to free drugs, and they have also
been found to be non-toxic to fibroblast cells. In taking inspiration from nature, the modification of
NPs with synthetic lipid coatings advances their therapeutic efficacy and potentiates the development
of effective drug delivery systems.
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4.2. Zwitterionic Polymers
Synthetic zwitterionic materials such as poly(carboxybetaine) (pCB) and poly(sulfobetaine) (pSB)
(Figure 7) have been proposed as PEG alternatives due to their strong hydration, conferring high
resistance to nonspecific protein fouling in addition to their inherently low immunogenicity [77,78].
Yang et al. demonstrated that zwitterionic poly(carboxybetaine acrylamide) (pCBAA) modified gold
NPs (GNPs) did not absorb serum proteins nor induce agglomeration, as compared to the significant
fouling and aggregation elicited by PEG (5 kDa) coated GNPs (PEG-GNPs) and oligo(ethylene glycol)
methacrylate (OEGMA) coated GNPs (OEGMA-GNPs). Consequently, pCBAA-GNPs were found to
be more stable in the bloodstream and thus had a longer circulation time than that of PEG-GNPs and
OEGMA-GNPs [77]. The immunogenicity of pCBAA-GNPs compared to PEG-GNPs, however, was
not investigated in this study.Polymers 2020, 12, x FOR PEER REVIEW 14 of 22 
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The prevention of protein absorption is paramount to decreasing opsonization that leads to
immune recognition and the clearance of therapeutic agents. Jiang et al. summarized the enhanced
anti-fouling properties of zwitterionic materials, in addition to various methods for the functionalization
of these materials to a myriad of surfaces towards biomedical applications [78]. The authors concluded
that zwitterionic materials, as the next generation of biomaterials, open new avenues for the design
and synthesis of anti-fouling agents for therapeutic drug delivery.
Polymers 2020, 12, 298 14 of 21
Table 1. A brief introduction to PEG alternatives when using various types of polymers.
PEG alternatives Advantages Limitations
Synthetic polymers
Polyoxazolines
(POX/POZ) - Tunable properties, biocompatibility,
better renal clearance, and
biodegradability [73]
- Impurities and high cost [73]
- Difficult to synthesize and
obtain approval by the FDA
[73]












- Lower degradation than PEG under UV
or ultrasound irradiation [76]
- Widely used in the cosmetic,
pharmaceutical and food industries [73]
- Not biocompatible if
molecular weight higher than
the kidney threshold [76]
- Higher rigid structure than
PEG, so less steric hindrance
[73]
Poly(glycerols)
(PG) - PG with hyperbranched structures
leading to high degrees of modification
[76]
- Does not increase blood viscosity [76]
- Improved circulation time [76]
- Does not induce ABC after repeated
exposure [73]
- Not biodegradable [73]
- High accumulation in tissues
[73,76]
Polyacrylamides
- Protein antifouling and biocompatible
[73]
- Not biodegradable [73]
- Acrylamide monomers
correlated to a variety of
severe neurotoxic effects [76]
- Some enhanced immune






PSA, HA, . . . )
Proteins (ELPs,
serum albumin,
CD47, . . . )
- Comparable shielding effects to PEG [75]
- Endogenously found within the body, so
they do not induce immune response [75]
- Biocompatible, biodegradable [75]
- Cell-like entities [75]
- Targeting capability in some specific
circumstances [75]
- Poorly studied as delivery vehicles [75]
- Not yet applied in a clinical setting [75]
Polyaminoacids
- Prolonged blood circulation, decreased
ABC, biodegradable [76]
- Candidates currently in clinical trials [76]
- Complement activation [76]







- Abundant functional groups, ease of
preparation, chemical stability, excellent
antifouling properties, abundance of raw
materials, low synthesis cost [78]
- Tunable properties for various purposes
in biomedical applications [78]
- Difficult synthesis of some polymers, e.g.,
2-methacryloyloxyethyl phosphorylcholine (MPC), . . . [78]
Zhang et al. interrogated an alternative stealth material consisting of polypeptides with a high
zwitterion density (PepCB) (Figure 8a) by utilizing uricase as a model protein to examine the different
pharmacokinetic and immunological profiles of uricase-modified PepCB and PEGylated uricase in
rats in vivo [79]. After 24 and 72 h, free uricase underwent rapid clearance from circulation, while the
uricase-modified PepCB and PEGylated uricase showed sustained activity, with the uricase-modified
PepCB achieving the longest half-life. This phenomenon was likely due to the stronger hydration
effect of carboxybetaine groups in comparison to ethylene glycol units, highlighting the advantageous
properties of zwitterionic PepCB over conventional PEG [79].
Positing that zwitterionic materials have been found to be superior to PEG for overcoming
undesirable immune responses after administration, Ou et al. designed poly(2-methacryloyloxyethyl
phosphorylcholine) (PMPC)/poly(β-amino ester) (PAE) modified poly(ε-caprolactone) (PCL) micelles
to form a mixed-shell micelles (MSMs) (Figure 8b) in order to evaluate their in vivo circulation and
determine anti-polymer antibody production [80]. Single PEG-PCL micelles (PEGSMs) and single
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PMPC-PCL micelles (PMPCSMs) were utilized as controls. After intravenous administration in a
rat model, MSMs with the optimal hydrophilic:hydrophobic ratio of 1:1 achieved the highest blood
retention time. Furthermore, PEGSMs were degraded in the blood much faster than PMPCSMs and
MSMs, as has been observed with other PEGylation-based therapeutic approaches. Han et al. recently
demonstrated the remarkable properties of zwitterionic polymers in protein modification by utilizing
zwitterlated interferon alpha-2a as an alternative therapeutic candidate to PEGylated interferon
alpha-2a. A prolonged circulation time and a reduced ABC was observed after repeated injections of
zwitterlated interferon alpha-2a compared to the PEGylated agent, and, importantly, zwitterlation
could mitigate interferon alpha-2a bioactivity loss in vitro over PEGylated interferon alpha-2a [63].
Overall, zwitterionic polymers hold great promise as PEG alternatives, but their application remains
limited, likely due to difficulties regarding their synthesis and conjugation.Polymers 2020, 12, x FOR PEER REVIEW 15 of 22 
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Through many research efforts to evaluate synthetic and natively-derived polymers as alternative
candidates to PEG, the polymers PG, polyaminoacids, polyacrylamides, PVP, zwitterionic polymers,
and polysaccharides have shown an analogous or improved performance compared to PEG and/or
PEGylated materials (Table 1) [73]. However, several limitations and undesirable side-effects (Table 1)
remain to be addressed for each candidate when engineering the hydrophilic shell of NPs for controlled
drug release.
5. Conclusions and Outlook
It is of no doubt that PEGylation has been one of the most powerful and useful strategies ever
developed in the field of drug delivery and bioconjugation. The functionalization of nanocarriers
with PEG enables the efficient delivery of hydrophobic drugs, improves circulation time, increases
mucus-penetration, and enhances the stability of biologically fragile therapeutics. Accordingly,
PEGylation has become a gold standard in drug/nanocarrier modification for developing drug delivery
systems. However, PEG immunogenicity is a growing issue that limits the efficacy of both commercially
available medications and future therapeutics that are currently in development and, critically, may
lead to adverse impacts on patient health.
As of writing, no alternative to PEG have been developed and translated into the clinic, although
recent studies have confirmed that the impact of PEG immunogenicity is becoming more widespread.
Recent insight into this immune response process has revealed that the anti-PEG antibodies that are
generated after initial administration contribute to the rapid clearance of the second dose (the ABC
phenomenon). Importantly, the ABC of PEGylated products can occur even at the first dose due to
pre-existing antibodies in patients who have contacted PEG in household or cosmetic products. Thus,
understanding the factors that impact anti-PEG antibody production is crucial for both researchers
and clinicians to develop novel drug vehicles or to adjust the route of administration and injection
schedule to ensure the highest treatment efficacy.
Identifying alternatives to PEG is also urgently needed. Much effort has been undertaken
to explore the capacity of synthetic polymers, natural polymers, and zwitterionic polymers in
drug/NP modification towards the development of innovative and effective drug delivery systems.
PG, polyaminoacids, polyacrylamides, PVP, zwitterionic polymers, polysaccharides, PHPMA and
POEGMA are promising candidates with comparable or superior properties to PEG. However,
key limitations that are associated with each of these candidates still remain and must be overcome to
confirm their non-immunogenicity and therapeutic benefits for biomedical applications. Accordingly,
the development of a standardized, universal nanoparticle platform that can be easily interfaced
with any potential candidate for immunogenicity screening would be optimal for the design and
interrogation of alternatives to PEG. Realizing such a platform will require the joint efforts of polymer
chemists, immunologists, and nanotechnologists, and it will take more time for these alternative
strategies to be translated into clinical applications. We envision that, in the near future, PEG will
remain the most widely used polymer in drug delivery and bioconjugation, while the search for PEG
alternatives will become a hot topic and an important race.
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